Buscar resultados de ensayos clínicos
Primary Central Nervous System Lymphoma - 27 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Condición: Primary CNS Lymphoma Fecha: 2016-10-13 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients Condición: Primary Central Nervous System Lymphoma Fecha: 2009-03-16 Intervenciones:
|
Recruiting |
Nombre del estudio: Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2014-12-05 Intervenciones: Drug: Rituximab, Methotrexate, Temozolomide Seven monthly R-MT cycles including high dose MTX (3.5g/m2, |
Recruiting |
Nombre del estudio: Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) Condición:
|
Recruiting |
Nombre del estudio: Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute Condición: Primary Central Nervous System Lymphoma Fecha: 2015-12-09 Intervenciones: Radiation: Standard treatment protocol with combined chemoradiation |
Enrolling by invitation |
Nombre del estudio: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Condición: Primary Central Nervous System Lymphoma Fecha: 2014-04-23 Intervenciones: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Recruiting |
Nombre del estudio: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Condición: Primary Central Nervous System Lymphoma Fecha: 2016-07-14 Intervenciones: Drug: R-IDARAM plus intrathecal chemotherapy R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubic |
Terminated |
Nombre del estudio: Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma Condición: Primary Central Nervous System Lymphoma Fecha: 2014-04-10 Intervenciones: Drug: Rituximab plus Temozolomide Treatment cycles will be repeated every 14 days (2 weeks) for the lead |
Completed |
Nombre del estudio: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Condición:
Intervenciones: Drug: Buparlisib (BKM120) Buparlisib 100 mg once daily. |
Recruiting |
Nombre del estudio: Treatment of Primary CNS Lymphoma Condición: Primary CNS Lymphoma (PCNSL) Fecha: 2013-10-08 Intervenciones:
|